MA46652A - Polythérapie pour l'inhibition de c3 - Google Patents
Polythérapie pour l'inhibition de c3Info
- Publication number
- MA46652A MA46652A MA046652A MA46652A MA46652A MA 46652 A MA46652 A MA 46652A MA 046652 A MA046652 A MA 046652A MA 46652 A MA46652 A MA 46652A MA 46652 A MA46652 A MA 46652A
- Authority
- MA
- Morocco
- Prior art keywords
- polytherapy
- inhibition
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662409357P | 2016-10-17 | 2016-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46652A true MA46652A (fr) | 2019-08-21 |
Family
ID=62019501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046652A MA46652A (fr) | 2016-10-17 | 2017-10-16 | Polythérapie pour l'inhibition de c3 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11338013B2 (fr) |
| EP (1) | EP3526328A4 (fr) |
| JP (2) | JP2020500157A (fr) |
| CN (2) | CN118217402A (fr) |
| AU (1) | AU2017346486B2 (fr) |
| BR (1) | BR112019007613A2 (fr) |
| CA (1) | CA3040917A1 (fr) |
| IL (1) | IL266012B2 (fr) |
| MA (1) | MA46652A (fr) |
| MX (1) | MX2019004500A (fr) |
| RU (1) | RU2019113301A (fr) |
| WO (1) | WO2018075373A1 (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| JP6968787B2 (ja) | 2015-10-07 | 2021-11-17 | アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. | 投与レジメン |
| BR112019007613A2 (pt) | 2016-10-17 | 2019-07-02 | Apellis Pharmaceuticals Inc | terapia de combinação para inibição de c3 |
| WO2018085208A1 (fr) | 2016-11-02 | 2018-05-11 | The Research Foundation For The State University Of New York | Procédés d'inhibition de virus à l'aide de compositions ciblant l'interaction tsg101-ubiquitine |
| US11040107B2 (en) * | 2017-04-07 | 2021-06-22 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| AU2018360697A1 (en) * | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
| KR20240167712A (ko) | 2017-12-15 | 2024-11-27 | 아펠리스 파마슈티컬스 인코포레이티드 | 투여 요법 및 관련 조성물 및 방법 |
| JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 糖タンパク質の製造 |
| SG11202010910QA (en) * | 2018-05-07 | 2020-12-30 | Alnylam Pharmaceuticals Inc | Extrahepatic delivery |
| JP2021534111A (ja) | 2018-08-10 | 2021-12-09 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症1型および関連状態を治療する方法 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| US11510939B1 (en) | 2019-04-19 | 2022-11-29 | Apellis Pharmaceuticals, Inc. | RNAs for complement inhibition |
| MX2022002397A (es) * | 2019-08-27 | 2022-08-25 | Silence Therapeutics Gmbh | Acidos nucleicos para inhibir la expresion de c3 en una celula. |
| JP7676377B2 (ja) | 2019-10-22 | 2025-05-14 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 補体成分C3 iRNA組成物およびその使用方法 |
| EP4069261A4 (fr) * | 2019-12-06 | 2023-05-03 | Sirnaomics, Inc. | Véhicule d'amarrage de peptides pour l'administration ciblée d'acides nucléiques |
| MX2022009870A (es) * | 2020-02-14 | 2022-11-07 | Apellis Pharmaceuticals Inc | Ácidos ribonucleicos (arn) para la inhibición del complemento. |
| IL307721A (en) * | 2021-04-20 | 2023-12-01 | Astrazeneca Ireland Ltd | Compounds and methods for inhibiting expression of component 3 |
| WO2022251484A1 (fr) * | 2021-05-26 | 2022-12-01 | Apellis Pharmaceuticals, Inc. | Traitement de troubles à médiation par le complément |
| MA71435A (fr) * | 2021-05-27 | 2025-04-30 | Apellis Pharmaceuticals, Inc. | Édition génomique du complément |
| AU2022420788A1 (en) | 2021-12-22 | 2024-05-16 | Boehringer Ingelheim International Gmbh | Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases |
| WO2024092105A2 (fr) | 2022-10-27 | 2024-05-02 | Arrowhead Pharmaceuticals, Inc. | Agents d'arni pour inhiber l'expression de composant c3 du complément (c3), compositions pharmaceutiques associées et méthodes d'utilisation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1960422B1 (fr) | 2005-11-28 | 2012-05-30 | The Trustees of The University of Pennsylvania | Analogues puissants de la compstatine |
| AU2006337093B2 (en) | 2005-12-22 | 2013-03-14 | Opko Pharmaceuticals, Llc. | Compositions and methods for regulating complement system |
| US20110190221A1 (en) * | 2008-03-28 | 2011-08-04 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| CN107050422B (zh) * | 2011-05-11 | 2021-11-09 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途 |
| WO2014078734A2 (fr) * | 2012-11-15 | 2014-05-22 | Apellis Pharmaceuticals, Inc. | Analogues de la compstatine réactifs aux cellules, à longue durée d'action ou ciblés et compositions et méthodes associées |
| CA2891673C (fr) * | 2012-11-15 | 2025-10-07 | Apellis Pharmaceuticals Inc | Analogues de la compstatine reactifs aux cellules, a longue duree d'action ou cibles et compositions et methodes associees |
| WO2014152391A1 (fr) | 2013-03-15 | 2014-09-25 | Apellis Pharmaceuticals, Inc. | Analogues de compstatine pénétrant dans les cellules et leurs utilisations |
| KR102344559B1 (ko) * | 2013-12-12 | 2021-12-31 | 알닐람 파마슈티칼스 인코포레이티드 | 보체 성분 iRNA 조성물 및 이의 이용 방법 |
| BR112019007613A2 (pt) | 2016-10-17 | 2019-07-02 | Apellis Pharmaceuticals Inc | terapia de combinação para inibição de c3 |
| AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
-
2017
- 2017-10-16 BR BR112019007613A patent/BR112019007613A2/pt unknown
- 2017-10-16 JP JP2019520579A patent/JP2020500157A/ja active Pending
- 2017-10-16 CA CA3040917A patent/CA3040917A1/fr active Pending
- 2017-10-16 CN CN202410080473.0A patent/CN118217402A/zh active Pending
- 2017-10-16 WO PCT/US2017/056708 patent/WO2018075373A1/fr not_active Ceased
- 2017-10-16 RU RU2019113301A patent/RU2019113301A/ru unknown
- 2017-10-16 MA MA046652A patent/MA46652A/fr unknown
- 2017-10-16 MX MX2019004500A patent/MX2019004500A/es unknown
- 2017-10-16 CN CN201780078063.0A patent/CN110249053A/zh active Pending
- 2017-10-16 EP EP17862431.8A patent/EP3526328A4/fr active Pending
- 2017-10-16 AU AU2017346486A patent/AU2017346486B2/en active Active
- 2017-10-16 US US16/342,477 patent/US11338013B2/en active Active
- 2017-10-16 IL IL266012A patent/IL266012B2/en unknown
-
2022
- 2022-04-12 US US17/719,074 patent/US20230009757A1/en not_active Abandoned
- 2022-09-09 JP JP2022144113A patent/JP2022188048A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019113301A (ru) | 2020-11-17 |
| JP2020500157A (ja) | 2020-01-09 |
| IL266012A (en) | 2019-06-30 |
| CN110249053A (zh) | 2019-09-17 |
| RU2019113301A3 (fr) | 2021-02-20 |
| AU2017346486B2 (en) | 2024-06-13 |
| IL266012B2 (en) | 2024-09-01 |
| JP2022188048A (ja) | 2022-12-20 |
| BR112019007613A2 (pt) | 2019-07-02 |
| US20230009757A1 (en) | 2023-01-12 |
| WO2018075373A1 (fr) | 2018-04-26 |
| MX2019004500A (es) | 2019-08-21 |
| IL266012B1 (en) | 2024-05-01 |
| EP3526328A1 (fr) | 2019-08-21 |
| US20200282012A1 (en) | 2020-09-10 |
| AU2017346486A1 (en) | 2019-05-23 |
| CN118217402A (zh) | 2024-06-21 |
| US11338013B2 (en) | 2022-05-24 |
| CA3040917A1 (fr) | 2018-04-26 |
| EP3526328A4 (fr) | 2020-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46652A (fr) | Polythérapie pour l'inhibition de c3 | |
| EP3446194A4 (fr) | Raccourcis d'application pour carplay | |
| MA47575A (fr) | Composés inhibiteurs d'oga monocyclique | |
| EP3324840A4 (fr) | Tensiomètre pour l'estimation de débit | |
| EP3423044A4 (fr) | Nanovaccin activant sting pour l'immunothérapie | |
| EP3430731A4 (fr) | Architecture d'iugw | |
| EP3347458A4 (fr) | Cochon multi-transgénique pour xénogreffe | |
| EP3337587A4 (fr) | Distributeur d'eau | |
| EP3630078A4 (fr) | Agents pour chimio-embolisation | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3773974C0 (fr) | Insert pour égout | |
| EP3277757A4 (fr) | Compositions pour l'inhibition de corrosion | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| MA49006A (fr) | Inhibiteurs d'ip6k | |
| EP3365403A4 (fr) | Combinaison d'inhibiteurs de cobalt pour un bombage amélioré | |
| EP3627918C0 (fr) | Radiorecherche d'extension de couverture pour ec-gsm | |
| EP3397288A4 (fr) | Méthodes pour diminuer l'expression de l'ataxine-2 | |
| MA39500A (fr) | Compositions à base d'extraits de plantes pour l'inhibition de la 5-alpha-réductase | |
| EP3500898A4 (fr) | Hélage d'un véhicule | |
| MA53648A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase | |
| EP3431808A4 (fr) | Butée d'arrêt | |
| EP3344650A4 (fr) | Aav-epo pour le traitement d'animaux de compagnie | |
| EP3408731A4 (fr) | Modes d'interaction pour interactions objet-dispositif | |
| FR3020758B1 (fr) | Composition pour ameliorer l'hygiene buco-dentaire |